Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSIGHTS: LCIG vs OMT for Non-Motor Symptoms in Advanced Parkinson's Disease
NCT02549092Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2015
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 3 trial of levodopa + carbidopa in Parkinson's disease (PD), sponsored by AbbVie Inc.. Started Oct 2015; status: completed.
02
Drugs
levodopa + carbidopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02549092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02549092.